Acknowledgements
We sincerely thank the individuals with PH3 who participated in PHYOX4. The study was supported by Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company (Lexington, MA, USA). Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Malcolm Darkes, Ph.D., of Ashfield MedComms, an Inizio company, and funded by Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company (Lexington, MA, USA). Dicerna and Novo Nordisk reviewed and provided feedback on the paper. The authors had full editorial control of the paper and provided their final approval of all content. We thank all PHYOX4 study investigators for their commitment to individuals with PH worldwide. 